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ABSTRACT
Background: Glypican-1 (GPC1) is expressed in pancreatic ductal adenocarcinoma 
(PDAC) cells and adjacent stromal fibroblasts. Recently, GPC1 circulating exosomes 
(crExos) have been shown to be able to detect early stages of PDAC. In this study, 
we investigated the usefulness of crExos GPC1 as a biomarker for PDAC.
Methods: Plasma was obtained from patients with benign pancreatic disease 
(n = 16) and PDAC (n = 27) prior to pancreatectomy, and crExos were isolated by 
ultra-centrifugation. Protein was extracted from surgical specimens (adjacent normal 
pancreas, n = 13; and PDAC, n = 17). GPC1 levels were measured using enzyme-linked 
immunosorbent assay (ELISA). 
Results: There was no significant difference in GPC1 levels between normal 
pancreas and PDAC tissues. This was also true when comparing matched pairs. 
However, GPC1 levels were enriched in PDAC crExos (n = 11), compared to the source 
tumors (n = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; P < 0.001). In addition, PDACs with 
high GPC1 expression tended to have crExos with higher GPC1 levels. Despite these 
findings, we were unable to distinguish PDAC from benign pancreatic disease using 
crExos GPC1 levels. Interestingly, we found that in matched pre and post-operative 
plasma samples there was a significant drop in crExos GPC1 levels after surgical 
resection for PDAC (n = 11 vs. 11; 97 ± 54 vs. 77.8 ± 32.4 pg/mL; P = 0.0428). 
Furthermore, we found that patients with high crExos GPC1 levels have significantly 
larger PDACs (>4 cm; P = 0.012). 
Conclusions: High GPC1 crExos may be able to determine PDAC tumor size 
and disease burden. However, further efforts are needed to elucidate its role as a 
diagnostic and/or prognostic biomarker using larger cohorts of PDAC patients.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a 
lethal disease and diagnostic difficulties result in late 
presentation and poor survival outcomes. Glypicans are a 
family member of heparan sulfate proteoglycans (HSPGs). 
HSPGs are diverse, ubiquitous and highly abundant 
macromolecules located on cell-surfaces, extracellular 
matrices and connective tissues [1]. They have been 
involved in broad cellular processes, including cell 
recognition, growth and adhesion, as well as proliferation, 
differentiation and morphogenesis [1]. Moreover, 
defective expression of HSPGs has been observed in 
human malignancies [2–4]. 
Earlier studies have shown that GPC1 is over-
expressed in human PDAC cells and their adjacent 
fibroblasts [4], as well as in a significant percentage 
of gliomas [3], breast [2] and ovarian tumors [5]. 
Furthermore, silencing of GPC1 in breast cancer [2] and 
PDAC cells [6] leads to a decrease in tumor growth and 
an attenuation of mitogenic responses. Indeed, down-
regulation of GPC1 in PDAC cells is associated with 
reduced proliferation and a reduction in tumor growth, 
angiogenesis and metastasis in vitro and in vivo [7]. 
Exosomes are small vesicles (50–140 nm in size) 
of endocytic origin that contain specific proteins, lipids 
and nucleic acids characteristic of their cellular origin [8]. 
They are secreted by different types of cells, including 
cancer cells, and they have been reported to be essential 
in cell-cell communication between cancer cells and their 
environment transferring information via their cargo [8]. 
Their main functions are to promote cancer development, 
stimulate angiogenesis, activate fibroblasts within the 
stroma, generate a pre-metastatic niche and inhibit host 
immune responses [9–11]. 
Recently, Melo et al. isolated circulating exosomes 
positive for glypican-1 (crExos GPC1+) from the serum of 
patients with PDAC and found that GPC1+ crExos could 
detect all stages of disease with unrivalled sensitivity and 
specificity [12]. Indeed, GPC1 was highly expressed on 
crExos in early and late stages of PDAC, compared to 
healthy controls (HC) and those with benign pancreatic 
disease [12].
In this study, we used ELISA to quantify GPC1 
levels in pancreatic tissues and crExos.
RESULTS
We isolated protein from PDAC tissues (n = 17) 
and adjacent normal pancreas (n = 13) taken at the time of 
pancreatectomy, and quantified GPC1 levels using ELISA 
(Figure 1A). Our results showed that there was no significant 
difference in GPC1 levels between normal pancreas and 
PDAC tissues (Figure 1A), and this was also true when 
comparing matched tissue pairs (n = 11 vs. 11; Figure 1B). 
Next, pre-operative plasma crExos GPC1 levels 
were measured from patients undergoing surgery for 
benign pancreatic disease (n = 16) and PDAC (n = 27). 
Our benign pancreatic disease group contained 7 patients 
with intraductal papillary mucinous neoplasms (IPMN; 4 
low/moderate grade dysplasia and 3 high grade dysplasia), 
6 with chronic pancreatitis (CP), and 3 with serous 
cystadenomas (SCA). However, contrary to previous 
reports [12], we did not observe any significant difference 
in plasma crExos GPC1 levels between benign and 
malignant disease (Figure 1C). Although this might be due 
to a Type II error, it certainly indicates that crExos GPC1 
may not be the best blood-based biomarker for diagnosing 
PDAC. Our assay achieved an area under the curve (AUC) 
of only 0.59, with a sensitivity of 74%, and a specificity of 
44% for detecting PDAC.
Following on from this, we investigated our matched 
samples (i.e. plasma and tissues from the same patient), 
and found that GPC1 protein levels were higher in PDAC 
crExos (n = 11) in comparison to the originating tumoral 
tissues (n = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; P < 0.001; 
Figure 2A). This confirmed that GPC1 is enriched in 
PDAC crExos, as previously reported [12].
We then measured crExos GPC1 levels in matched 
pre and post-operative plasma samples (n = 11 vs. 11). 
These post-operative samples were taken at a mean of 48.7 
days (range 28–82 days) after pancreatic resection, prior 
to any adjuvant therapy. We found that in these patients 
there was a drop in crExos GPC1 after surgical resection 
(97 ± 54 vs. 77.8 ± 32.4 pg/mL; P = 0.0428; Figure 2B). 
Although, we found no significant difference in post-
operative crExos GPC1 levels based on resection margin 
status: R0 (n = 7) 76.2 ± 36.6 vs. R1 (n = 4) 80.7 ± 28.4 
pg/mL; P > 0.05 (Supplementary Figure 1). This suggests 
that crExos GPC1 could be useful at monitoring gross 
tumor burden, but not microscopic residual disease.
Next, we hypothesized that patients with high 
crExos GPC1 pre-operatively may originate from PDACs 
with high GPC1 levels. We dichotomized tissue GPC1 
levels into low or high expression in our 17 PDAC 
patients. We then assigned our 11 patients with matched 
crExos samples, according to whether these patients had 
high or low GPC1 expressing PDACs. However, we 
were unable to show a statistical difference in crExos 
GPC1 levels when stratifying by tumoral expression, 
although the numbers of patients in this analysis were 
small (Figure 2C). 
Finally, we correlated both PDAC tissue GPC1 
levels (n = 17) and pre-operative crExos GPC1 expression 
(n = 27) with clinico-pathological factors. This showed 
that tissue GPC1 levels were not significantly associated 
with any clinico-pathological factor (data not shown). 
However, high pre-operative crExos GPC1 expression 
levels were associated with larger tumor sizes (>4 cm; P 
= 0.012; Table 1).
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DISCUSSION 
In this study, we found that crExos GPC1 levels 
were not elevated in PDAC compared to benign pancreatic 
disease, when measured by ELISA. However, crExos 
GPC1 levels may be clinically useful for determining 
PDAC tumor size and disease burden. Previous studies 
have demonstrated an over-expression of GPC1 in PDAC 
tissues at the mRNA and protein levels [4, 13, 14]. The 
recent report by Melo et al. identified crExos GPC1+ as 
a highly accurate biomarker for the early detection of 
PDAC [12]. However, the techniques that they employed 
would be quite difficult to reproduce in a standard hospital 
laboratory, including the use of anti-GPC1 antibody 
labelled beads to bind crExos GPC1+, and subsequent 
quantification by flow cytometry. Therefore, we used 
ELISA to establish a more clinically amenable assay for 
the quantitative analysis of GPC1 levels in plasma crExos, 
whilst still being highly sensitive and reproducible. 
We first examined GPC1 levels in adjacent normal 
pancreas and PDAC tissues. However, we were unable 
to differentiate between tissue types using GPC1 levels 
measured by ELISA. This may be due to the use of 
macro-dissected bulk tissues for protein extraction and 
GPC1 quantification. We may have had a more accurate 
analysis using laser micro-dissected tissues, since it is 
possible the adjacent normal pancreas could have had 
areas of desmoplastic stroma that were not easily visible 
during macro-dissection, and could have influenced the 
result. Alternatively, our ELISA assay may have detected 
GPC1 that had “leaked over” from the PDAC side of 
the transection margin. Kleeff et al. showed that there 
is an abundance of GPC1 in the fibroblasts surrounding 
PDAC and suggested that these cells participate in the 
storage of this growth factor [4]. As PDAC cells invade 
the surrounding stroma, this allows release of GPC1, 
leading to mitotic stimulation and tumor progression [4]. 
Indeed, Lu et al. found that in the TCGA analysis, which 
used bulk tissues, that GPC1 mRNA levels were higher 
in those patients with PDAC on a background of chronic 
pancreatitis (CP) [14]. They speculated that perhaps this 
inflammation increased GPC1 levels in these tissues, 
and also that there may have been some contamination 
from the desmoplastic stroma, which could have elevated 
GPC1 levels even further [14]. Immunohistochemistry 
(IHC), whilst being semi-quantitative, is able to visualise 
cellular localization of protein expression, and could be 
considered more accurate for determining differential 
expression between tissues that are not micro-dissected. 
Lu et al. determined distribution of GPC1 protein levels 
by IHC in normal pancreata (n = 2), CP (n = 4), adjacent 
normal pancreas (n = 169), and PDAC (n = 186) [14]. 
In this analysis, they found that 59.7% (111/186) of the 
PDAC tumors had positive cytoplasmic and membrane 
immunostaining for GPC1, whilst non-neoplastic tissues 
barely showed any GPC1 expression (2/175) [14]. In 
the positively stained PDAC tissues, 51.4% (57/111) 
had weak, 35.1% (39/111) had moderate, and 13.5% 
(15/111) had strong staining of GPC1 [14]. The other 
40.3% (75/186) of PDACs had no immunostaining for 
GPC1 [14]. Similarly, Duan et al. found that whilst GPC1 
expression was significantly higher in PDAC vs. normal 
pancreas, 43.5% (27/62) of PDACs were still negative for 
GPC1 [13]. Therefore, only ~60% of PDACs are positive 
Figure 1: Glypican-1 (GPC1) expression in pancreatic tissues and circulating exosomes (crExos). Displayed are the GPC1 
protein levels measured by ELISA for (A) Adjacent normal pancreas (NP; n = 13) vs. PDAC (n = 17) tissues and (B) a sub-analysis for 
matched patient samples (n = 11 vs. 11). (C) GPC1 was measured in crExos from patients with benign pancreatic disease (BPD; total n = 
16: intraductal papillary mucinous neoplasms (IPMN), n = 7; chronic pancreatitis (CP), n = 6; serous cystadenoma, SCA, n = 3); and PDAC 
(n = 27). There was no significant difference between BPD vs. PDAC, or between disease groups using a one-way analysis of variance 
(ANOVA) and Tukey’s post-hoc honest significant difference (HSD) test. Scatterplots show expression for each sample and the horizontal 
lines represent the mean expression level and standard deviation. 
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for GPC1 and those with GPC1 over-expression appear 
to have a more aggressive phenotype. Indeed, high GPC1 
expression in PDAC tissues has been associated with 
perineural invasion (PNI), high grade, large tumor size 
and poor overall survival (OS) after surgical resection 
[13, 14]. This is unsurprising as GPC1 has been shown 
to enhance proliferation and migration in vitro [4], and 
promote tumor growth, angiogenesis, and invasion in 
mouse models of PDAC [15]. Based on these data, we 
correlated tissue GPC1 levels in our PDACs with clinico-
pathological factors. However, we were unable to find any 
significant association, probably due to the small number 
of patients included. 
Next, we sought to further investigate the ability 
of crExos GPC1 to diagnose PDAC. Several authors 
have asked for the results from Melo et al. [12] to be 
confirmed in an independent series of patients [16, 17]. 
These additional data would help to validate crExos GPC1 
as a blood-based biomarker for the detection of PDAC 
[18]. Herreros-Villanueva et al. also suggested that the 
methodology should be optimized in order to achieve an 
accurate and less expensive biomarker, which is available 
in standard clinical laboratories, such as a simple blood 
test, without the need for exhaustive ultra-centrifugation 
steps and/or complicated staining techniques [18]. We 
have made the first step towards this by measuring crExos 
GPC1 levels using ELISA, which was a sensitive, simple 
and reproducible technique. However, we still employed 
recognised ultra-centrifugation techniques to isolate plasma 
crExos [19]. Using these methods, we were able to confirm 
that crExos are enriched in GPC1 compared to their 
originating PDAC tissues. The presence of crExos GPC1+ 
has been reported to be near perfect for distinguishing 
PDAC from benign pancreatic disease and healthy controls, 
with an AUC of 1.0, and 100% sensitivity and specificity 
[12]. However, when we measured pre-operative 
crExos GPC1 levels by ELISA in patients undergoing 
pancreatectomy for benign pancreatic disease and PDAC, 
we were unable to discriminate between the two groups 
with any statistical significance, and found a disappointing 
AUC of 0.59. This may have been due to small sample 
sizes, or that ELISA was too insensitive to accurately 
quantify crExos GPC1 levels. Interestingly, when Melo 
et al. [12] used an ELISA assay to detect circulating free 
GPC1 in the serum of healthy controls, and patients with 
benign pancreatic disease and PDAC, this exhibited lower 
sensitivity and specificity (82% and 75% respectively; 
AUC 0.78) for detecting PDAC compared to measuring 
crExos GPC1+ by flow cytometry. Our study has been 
the first to use ELISA to quantify crExos GPC1 levels. 
Remarkably, Lai et al. also found considerable overlap in 
pre-operative plasma crExos GPC1 levels between healthy 
controls, CP and PDAC patients when measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), 
resulting in an AUC of 0.75 for detecting PDAC [20]. 
Thus, crExos GPC1 may not have the high sensitivity and 
specificity for detecting PDAC as previously reported [12], 
but this could be dependent on the methods used. Melo et 
al. found that crExos GPC1+ levels were consistently higher 
in patients with intraductal papillary mucinous neoplasms 
(IPMN), compared to healthy controls, or patients with 
CP or SCA [12]. Our benign pancreatic disease group 
contained 7 patients with IPMN, 6 with CP, and 3 with 
SCA. However, we did not find a significant difference 
in crExos GPC1 levels between these groups after using a 
multiple comparison test.
Figure 2: Circulating exosomal Glypican-1 (GPC1) is a marker of PDAC disease burden. (A) In matched samples, 
Glypican-1 (GPC1) is enriched in circulating exosomes (crExos; n = 11) compared to their source PDAC tissues (n = 11; ***P < 0.001). 
(B) The crExos GPC1 levels were found to decrease post-operatively after surgical resection when compared to matched pre-operative 
samples from the same patients (n = 11 vs. 11; *P < 0.05). (C) PDAC tissues with high GPC1 expression did not have crExos with higher 
GPC1 levels in matched samples. 
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Tumoral GPC1 levels have been correlated 
with worse biological characteristics in PDAC. We 
hypothesized that crExos GPC1 levels may also be 
associated with clinico-pathological features, and found 
that high crExos GPC1 expression was associated with 
larger tumor sizes (>4 cm). Indeed, Lu et al. previously 
observed that higher tumoral GPC1 protein levels were 
found in very large PDACs (>6 cm) [14]. Interestingly, 
when we examined matched tumor and plasma samples, 
we found that PDACs with high GPC1 protein levels 
tended to produce crExos with higher GPC1 levels (127.7 
± 66.8 vs. 71.5 ± 24.9 pg/mL), but this was not statistically 
significant. Looking at the longitudinal plasma samples 
collected pre- and post-operatively from these patients, we 
found that ~7 weeks after pancreatic resection there was 
a significant reduction in crExos GPC1 levels. However, 
there was no significant difference in post-operative 
crExos GPC1 levels when comparing R0 vs. R1 resections. 
These data indicate that crExos GPC1 may be a useful 
biomarker for estimating gross PDAC tumor burden, and 
are in line with findings by Melo and colleagues [12]. 
Furthermore, Melo et al. found a significant decrease in 
crExos GPC1+ levels at 7 days after surgical resection of 
a PDAC, or even an IPMN [12]. Lai et al. found that after 
resection of a PDAC there was a non-significant trend 
towards reduced crExos GPC1 levels post-operatively, 
but they admit this was probably because they only 
investigated 3 patients in this analysis [20]. Since crExos 
GPC1 levels are also elevated in patients with breast [12] 
and colorectal cancers [21], this suggests that it would not 
be a good biomarker for screening for PDAC, but rather 
to monitor known disease or perhaps be used as an adjunct 
investigation in patients with suspected PDAC. 
Cancer exosomes are mediators of cell-to-cell 
communication and carry tumor-promoting cargo to 
recipient cells [10]. Proteins, lipids, DNA and RNAs 
(mRNAs, microRNAs and other non-coding RNAs) 
are present in tumor-derived exosomes and are crucial 
players in exosome biology. Therefore, exosomes have the 
potential to be clinically useful diagnostic and/or prognostic 
biomarkers in cancer. Indeed, this may also be cost 
effective, as the isolation and use of exosomal biomarkers 
from patients would certainly be cheaper, less invasive, and 
potentially more sensitive and specific than many of the 
current clinical diagnostic tests [22]. Melo and colleagues 
reported that crExos GPC1+ is an attractive candidate for 
identifying patients with early and more established PDAC 
[12], as well as potentially malignant pancreatic precursor 
lesions (i.e. mucinous cystic neoplasms) [23]. However, 
we agree with Diamandis and co-authors [17] that there 
are still no biomarkers that perform with 100% specificity 
and sensitivity for PDAC. Indeed, we have shown that 
Table 1: Summary of the clinico-pathological characteristics of the PDAC crExos cohort
Variables Subcategory PDAC crExos cohort n (%)
PDAC crExos 
Low GPC1  
n (%)
PDAC crExos 
High GPC1 n (%) P value
a
All casesb 27 13 14 −
Age, y ≤60 6 (22.2) 3 (50) 3 (50)
0.918
>60 21 (77.8) 10 (47.6) 11 (52.4)
Sex Female 11 (40.7) 6 (54.5) 5 (45.5)
0.581
Male 16 (59.3) 7 (43.8) 9 (56.2)
Differentiation
grade
Low (G1/2)
High (G3)
12 (44.4)
15 (55.6)
6 (50)
7 (46.7)
6 (50)
8 (53.3) 0.863
Lymph-node
Status (N)
Absent (N0) 
Present (N1)
9 (33.3)
18 (66.7)
5 (55.6)
8 (44.4)
4 (44.4)
10 (55.6) 0.586
Tumor Size, cm <4 14 (51.9) 10 (71.4) 4 (28.6)
0.012
>4  13 (48.1) 3 (23.1) 10 (76.9)
Perineural
Invasion (PNI) No 8 (29.6) 4 (50) 4 (50) 0.901
Yes 19 (70.4) 9 (47.4) 10 (52.6)
Resection margin
Status (R)
Negative (R0) 17 (63) 9 (52.9) 8 (47.1)
0.516
Positive (R1) 10 (37) 4 (40) 6 (60)
PDAC, pancreatic ductal adenocarcinoma; AJCC, American Joint Committee on Cancer; crExos, circulating exosomes; 
GPC1, Glypican-1. aPearson Chi-Square test; bThese samples were all pre-operative plasma crExos.
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crExos GPC1 measured by ELISA may be useful as a 
marker of tumor burden and response to surgical resection, 
but we were unable to distinguish benign pancreatic 
disease from PDAC pre-operatively. It is now essential 
to standardize methods for exosome isolation and crExos 
GPC1 quantification, in order to ultimately validate this 
biomarker as clinically relevant for patients with suspected 
pancreatic tumors.
METHODS
Ethics statement
This study was approved by a London Research 
Ethics Committee (Camden & Islington 09/H0722/77, 
26th November 2009). All patients signed an informed 
consent form for research prior to a venepuncture being 
performed and tissue sampling. 
Study population 
The clinico-pathological features of selected patients 
are summarized in Table 1. A total of 27 PDAC patients 
with stage T2-3, N0-1, M0 underwent pancreatic resection. 
Plasma and tissue samples
Pre-operative blood samples from 16 patients 
with benign pancreatic disease and 27 patients with 
PDAC undergoing pancreatic surgery were obtained at 
Hammersmith Hospital. Blood (5–10 ml) was collected 
into EDTA-coated tubes for all patients prior to surgery, 
and ~7 weeks following surgery for PDAC for 11 patients. 
Specimens were either placed on ice or in a refrigerator 
(4° C), or taken directly to the lab and rapidly processed 
by centrifugation (1000 × g for 10 min) at 4° C (within 2 
hours of collection). Plasma supernatants were collected 
and stored at −80° C until required. Tissue extracts from 
patients (PDAC, n = 17; and adjacent normal pancreas, 
n = 13) were obtained intra-operatively at Hammersmith 
Hospital and stored directly at −80° C until required. 
There were matched samples for 11 patients.
Protein extraction from tissues
Tissue lysates were prepared from minced frozen 
samples of PDAC and adjacent normal pancreas on ice 
in a lysis buffer (50 mM Tris [pH 7.6], 0.5 M NaCl, 
0.1% sodium dodecyl sulfate [SDS], 0.02% NaN3, 
1 mM phenylmethanesulfonyl fluoride [PMSF], 5 mM 
ethylenediaminetetraacetic acid [EDTA], and 1 mM 
iodoacetamide) containing protease inhibitor cocktail 
(Roche, Basel, Switzerland), homogenized overnight 
at 4° C, and centrifuged at 10,000 g for 10 min at 4° C. 
Supernatants were kept frozen at −80° C until required. 
Protein concentrations of the lysates were determined 
using a Pierce BCA assay kit (Thermo Fisher Scientific, 
Rockford, USA). 
Isolation of exosomes and quantification of 
GPC1
Isolation of crExos from the plasma (1–1.5 ml) of 
patients with PDAC and BD was performed by ultra-
centrifugation using the protocols by Théry et al. [19]. 
GPC1 levels in crExos and tissue lysates were quantified 
by enzyme-linked immunosorbent assay (ELISA; E9038h; 
2BScientific Ltd, UK) according to the manufacturer’s 
protocol. The tetraspanins CD9, CD63, and CD81 are 
classically used as exosome markers [24]. We used the 
Exo-Check antibody array (System Biosciences, UK) 
to check exosomal marker expression following the 
manufacturer’s protocol. This array has 12 pre-printed 
spots and 8 antibodies for known exosome markers 
(CD63, CD81, ALIX, FLOT1, ICAM1, EpCAM, ANXA5 
and TSG101), and a positive control spot derived from 
human serum exosome proteins. Supplementary Figure 2 
shows representative blots confirming exosomal markers 
in our plasma crExos samples, including CD63 and/or 
CD81 expression.
Statistical analyses
All experimental data are reported as means; error 
bars represent standard deviation (SD). Comparisons 
between groups were performed using paired or unpaired, 1 
or 2-tailed Student’s t-tests where appropriate. Correlations 
between GPC1 expression and clinico-pathological 
characteristics were calculated using χ2 test. To compare 
multiple groups, a one-way analysis of variance (ANOVA) 
and Tukey’s post-hoc honest significant difference (HSD) 
test was used. Statistical analyses were performed using 
GraphPad Prism 7.0 or SPSS for Windows version 20.0 
(IBM SPSS Statistics, Chicago, IL, USA). P-values < 0.05 
were considered significant.
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